ROANOKE, Va. – Vectorial Corp., a biotechnology company focused on developing new treatments for heart failure, has received a $50,000 award from the Virginia Innovation Partnership Corp. (VIPC) to advance its therapeutic development program.

The funding is part of VIPC’s efforts to help early-stage companies in Virginia move promising scientific innovations toward commercialization and clinical application.

Vectorial’s research centers on the role of cellular energy metabolism in cardiac function. In heart failure, declining mitochondrial energy production reduces heart muscle cells’ ability to sustain the mechanical work required for effective pumping, contributing to a progressive loss of cardiac performance.

The company is developing a therapeutic strategy designed to improve the metabolic efficiency of heart muscle cells and support the energetic demands of cardiac contraction. In preclinical studies, this approach has shown the potential to preserve cardiac function and limit structural changes associated with disease progression.

“The VIPC award provides important momentum as we continue advancing our research program,” said Alexey Zaitsev, Ph.D., chief executive officer and co-founder of Vectorial Corp. “Support from organizations committed to strengthening Virginia’s innovation ecosystem plays a critical role in helping early-stage biotechnology companies move new therapeutic ideas toward development.”

Vectorial will use the funding to expand its research and development activities as it continues to evaluate the potential of its technology in preclinical models.

Vectorial Corp. is developing therapies designed to address the biological mechanisms underlying heart failure by improving the energetic capacity of cardiac muscle.